Influenza Virus Inhibitor

PPQ-581 is an anti-influenza agent with an EC₅₀ of 1 μM for preventing virus-induced cytopathic effects. PPQ-581 inhibits viral protein synthesis. PPQ-581 blocks the RNP nuclear export and cytoplasmic RNP aggregation.

Influenza virus-IN-10 is a dual-target antiviral agents for influenza that targets both PA_C (K_D = 8.9 μM) and NP (K_D = 52.5 μM) simultaneously. Influenza virus-IN-10 exhibits an EC₅₀ values of 1.64 μM) against influenza A virus (H1N1, A/WSN/33) and broad-spectrum activity against other influenza strains, including influenza B virus and multiple subtypes of influenza A.

Cap-dependent endonuclease-IN-29 is a Cap-dependent endonuclease inhibitor and a stereoselective synthetic intermediate. Cap-dependent endonuclease-IN-29 can be used in research on viral infections.

AEBSF hydrochloride (Standard) is the analytical standard of AEBSF hydrochloride (HY-12821). This product is intended for research and analytical applications. AEBSF hydrochloride is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.

PAC/NP-IN-1 (Compound 30) is a dual-target anti-influenza agent that specifically binds to nucleoprotein (NP) and the C-terminal domain of PA protein (PAc). PAC/NP-IN-1 inhibits influenza A virus A/WSN/33 (H1N1) (EC₅₀ = 3.63 μM, IC₅₀ = 3.08 μM). PAC/NP-IN-1 can be used for the study of influenza infection.

Fluvirucin B4 is an antibiotic against influenza A virus.

UNC0638 hydrate selectively inhibits G9a and GLP histone methyltransferases with IC₅₀ of 15 nM and 19 nM, respectively. UNC0638 hydrate inhibits TNBC cell invasion and migration in vitro. UNC0638 hydrate is also an inhibitor of EHMT1/2 and induces fetal hemoglobin (HbF) expression in human erythroid progenitor cell culture. In addition, UNC0638 hydrate has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus) activities, with excellent potency and selectivity against multiple epigenetic and non-epigenetic targets.

Cbz-QFR-kbt is a ketone-based benzothiazole ketone inhibitor of TMPRSS2, with an IC₅₀ value of 0.42 nM. Cbz-QFR-kbt also has inhibitory activity against Matriptase, Hepsin, HGFA, and Factor Xa, with IC₅₀ values of 1, 1.3, 85, and 85 nM respectively. Cbz-QFR-kbt shows significant inhibitory effects against SARS-CoV-2 and H1N1 (IC₅₀ = 60 nM). Cbz-QFR-kbt can be used in antiviral research.

Influenza A virus-IN-15 (Compound 9b), a quinoline derivative, is a broad-spectrum inhibitor of influenza A viruses with acceptable cytotoxicity (IC₅₀: 0.88-6.33 μM). Influenza A virus-IN-15 can inhibit the transcription and replication of viral RNA and is used in research for its antiviral effects against influenza A viruses (IAV).

Cinanserin (hydrochloride) (Standard) is the analytical standard of Cinanserin (hydrochloride) (HY-100943). This product is intended for research and analytical applications. Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity 5-HT2 receptor antagonist with a Ki of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the 5-HT2 than for the 5-HT1 receptor (Ki of 3500 nM). Cinanserin is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (C05) is a broad-spectrum neutralizing antibody that targets multiple influenza A HA subtypes. Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (C05) is applicable to research related to influenza A virus infection.

U0126 (Standard) is the analytical standard of U0126 (HY-12031A). This product is intended for research and analytical applications. U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor.

KJ001-12a is an orally active anti-influenza agent with activity against influenza A and B strains. KJ001-12a acts as an RNA-dependent RNA polymerase inhibitor that reduces the expression levels of viral M2 mRNA and vRNA. KJ001-12a shows low sensitivity to the loss of inhibitory activity caused by the I38T mutation. KJ001-12a is applicable for influenza-related research.

VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Umifenovir (Standard) is the analytical standard of Umifenovir. This product is intended for research and analytical applications. Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro. Umifenovir shows anti-inflammatory activity.

Antiviral agent 87 is a potent antiviral agent with low cytotoxicity in host cells. Antiviral agent 87 stabilizes prefusion HA conformation, blocks viral membrane fusion and host cell entry, and inhibits entry and replication of diverse influenza A virus subtypes. Antiviral agent 87 can be used for the research of influenza A virus infection.

Caesalmin E is a natural cassane furanoditerpene with anti-Para3 (Parainfluenza virus type 3) virus activities.

Amantadine (hydrochloride) (Standard) is the analytical standard of Amantadine (hydrochloride). This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) hydrochloride is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine hydrochloride inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine hydrochloride also has anti-orthopoxvirus and anticancer activity. Amantadine hydrochloride can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research.

BMS-199945 is a influenza virus fusion inhibitor with the IC₅₀ values of 0.57 μM and approximately 1 μM aganist influenza A/WSN/33 virus-induced hemolysis of chicken RBC and in the trypsin protection assay, respectively.

KIN1148 (Standard) is the analytical standard of KIN1148 (HY-101950). This product is intended for research and analytical applications. KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.